Jubilant Pharma arm to raise $400 mn loan from StanChart Bank to repay debt
While the term loan and bonds aggregate to $350 million, about Rs 2,787 crore, the company is raising another tranche of $50 million (about Rs 400 crore) for capital expenditure.
- Jul 14, 2022,
- Updated Jul 14, 2022 10:04 AM IST
Jubilant Pharma Holdings on Wednesday said it has signed an agreement with Standard Chartered Bank for a five-year loan of $400 million, about Rs 3,186 crore. The majority of the amount will be used for repayment of existing term loan and debt bonds, the company said in a regulatory filing.
While the term loan and bonds aggregate to $350 million, about Rs 2,787 crore, the company is raising another tranche of $50 million (about Rs 400 crore) for capital expenditure.
"Jubilant Pharmova Limited's wholly-owned subsidiary Jubilant Pharma Limited today announced that its subsidiary Jubilant Pharma Holdings Inc (JPHI) has entered in an agreement with Standard Chartered Bank for a five-year loan facility for repayment of existing term loan and bonds aggregating $350 million and additional tranche of $50 million for future growth capex," the company said.
Jubilant Pharma Holdings on Wednesday said it has signed an agreement with Standard Chartered Bank for a five-year loan of $400 million, about Rs 3,186 crore. The majority of the amount will be used for repayment of existing term loan and debt bonds, the company said in a regulatory filing.
While the term loan and bonds aggregate to $350 million, about Rs 2,787 crore, the company is raising another tranche of $50 million (about Rs 400 crore) for capital expenditure.
"Jubilant Pharmova Limited's wholly-owned subsidiary Jubilant Pharma Limited today announced that its subsidiary Jubilant Pharma Holdings Inc (JPHI) has entered in an agreement with Standard Chartered Bank for a five-year loan facility for repayment of existing term loan and bonds aggregating $350 million and additional tranche of $50 million for future growth capex," the company said.